First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors

Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells

(2018) Carlos M. Galmarini et al.   BMC CANCER

Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review

(2017) Nicolas Kerckhove et al.   Frontiers in Pharmacology

Microtubule destabilising agents: far more than just antimitotic anticancer drugs

(2016) Darcy Bates et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors

(2014) Marta Martínez-Díez et al.   BIOCHEMICAL PHARMACOLOGY

Targeting Microtubules by Natural Agents for Cancer Therapy

(2014) E. Mukhtar et al.   MOLECULAR CANCER THERAPEUTICS

A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs

(2014) A. E. Prota et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration

(2014) A. J. M. Beijers et al.   SUPPORTIVE CARE IN CANCER

New Interfacial Microtubule Inhibitors of Marine Origin, PM050489/PM060184, with Potent Antitumor Activity and a Distinct Mechanism

(2013) Benet Pera et al.   ACS Chemical Biology

Isolation and First Total Synthesis of PM050489 and PM060184, Two New Marine Anticancer Compounds

(2013) María Jesús Martín et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients

(2012) A. A. Argyriou et al.   ANNALS OF ONCOLOGY

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Use of Body Surface Area for Assessing Extracellular Fluid Volume and Glomerular Filtration Rate in Obesity

(2009) A. Michael Peters et al.   AMERICAN JOURNAL OF NEPHROLOGY

Antivascular Actions of Microtubule-Binding Drugs

(2009) E. L. Schwartz   CLINICAL CANCER RESEARCH

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY